The study was made to evaluate bone turnover in systemic lupus erythematosus (SLE) patients undergoing long-term glucocorticoid therapy. Thirty-eight female patients with established SLE were compared with a control group consisting from 160 age-matched healthy women. Serum concentrations of proinflammatory cytokines: interleukin-la, interleukin-6, tumor necrosis factor-oc granulocyte-macrophage colony stimulating factor (GM-CSF) and some biochemical markers of osteoporosis (osteocalcin, total and bone alkaline phosphatase, procollagen type I carboxyterminal propeptide, carboxyterminal telopeptides of type I collagen -CTx) were measured. Additionally, morning urine excretions of deoxypyridinoline and calcium/creatinin ratios were determined. The forearm densitometry (DXA) was performed in all patients. Bone mineral content (BMC) and bone mineral density (BMD) in the SLE group was not significantly different from the controls, and no relationship was found between the glucocorticoid exposure and the BMC/BMD. However, biochemical markers of bone resorption -CTx and calcium/creatinin ratio -were significantly increased in the patient group. Our results suggest that BMD/BMC is preserved in glucocorticoidtreated SLE patients despite accelerated bone turnover.
INTRODUCTION
Systemic Lupus Erythematosus (SLE)b is a chronic, inflammatory disease characterized by a wide range of immunological changes and autoimmune phenomena [1, 2] . Glucocorticoids (gcs) still remain the first-choice treatment option for SLE.
They possess strong anti-inflammatory and immunosuppressive properties, mainly due to their profound effect on the production of proinflammatory cytokines [3] [4] [5] . Although very effective, gcs treatment causes a number of adverse events. For instance, gcs have an inhibitory effect on the bone turnover and may induce osteoa To whom all correspondence should be addressed: Izabela Korczowska BMC, bone mineral content; BMD, bone mineral density; CTx, carboxy-terminal collagen crosslinks; Dpd, deoxypyridynoline; DXA, densitometry; gcs, glucocorticoids; GM-CSF, granulocyte-macrophage colony stimulating factor; IL-1-a, interleukin-1-a;  Serum levels of acute-phase reactants: ca-l-acid-glycoprotein (AGP) and a-ichymotrypsine (ACT) were measured by rocket immunoelectrophoresis [8] . Glycosylation profile of a-l-acid-glycoprotein was determined using affinity immunoelectrophoresis with the lectin concanavalin A as described by B0g-Hansen [9] and the results were expressed as reactivity coefficients (AGP-RC). Bone Step ELISA kits from Osteometer Biotech (Denmark). Serum tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), interleukin-loc (IL-la), and granulocyte/monocyte colony stimulating factor (GM-CSF) were measured by ELISA using the Quantikine kit purchased from R&D System (USA).
Densitometry: The bone mineral density (BMD) and bone mineral content (BMC) of the forearm were measured using standard DXA technique (DTX-200, Osteometer, Denmark).
Statistical analysis: The Mann-Whitney U, the Kruskal-Wallis ANOVA, and the Fisher's exact test were used to compare variables (differences were considered significant at p < .05). To determine the correlation between the variables the Spearman test was used (results were consider positive for r > 0.5 at p < .05).
RESULTS
The differences in BMC and BMD between SLE patients and age-matched healthy controls were not statistically significant (Table 1) . We found eight SLE patient with osteoporosis (age, 60.3 ± 9.4 years) and 22 woman with osteoporosis in healthy group (63.5 ± 6.5 years), but there were no differences in BMC and BMD between this two group.
The BMC and BMD were decreased in postmenopausal women in either patient and control groups ( Table 2) . Because of correlation between BMC and age of menopause the changes in BMC depending on age have been analyzed in the group of SLE patients and healthy subjects. The correlation between BMC and age suggests faster bone loss in SLE patients, however it was not found to be statistically significant ( Figure 1 ). Table 3 . In the SLE group, increase in the IL-6 and TNF-a levels was observed. The levels of other cytokines were similar in patients and controls (Table  4) . No significant differences were found between the patients and the healthy controls in the levels of BGP, AP and AP-B. Two markers of bone resorption (CTx and Ca/Crea ratio) were significantly increased in SLE compared to control subjects (Table 5 ). The differences in pre-and postmenopausal patients are shown on Table 6 . We divided our patients with SLE into three groups: eight with osteoporosis, 15 with osteopenia, and 15 without osteoporosis and osteopenia. Two markers of bone metabolism (AP-B and Dpd) and serum levels of IL-6 were significantly increased in SLE with osteoporosis compared to SLE without osteoporosis and osteopenia (Table 7) .
Statistically significant correlation between total dose of gcs and the BMC was not observed (r = -0.065, NS). However, statistically significant correlation were observed between the levels of CRP and CTx (r = 0.244, p < .01) and AGP and CTx (r = 0.272; p < .01). There were also statistically significant correlation between CTx and IL-6 (Figure 2 ), CTx and BGP, and the AP-B activity and the BGP level in the group of SLE patients and the control group (Figure 3) . Table 5 . The levels of markers of bone tissue metabolism: osteocalcin (BGP), alkaline phosphatase (AP) and alkaline phosphatase-bone formation (AP-B), procollagen type I carboxyterminal propeptide (PIPC), carboxyterminal telopeptides of type I collagen (CTx), deoxypyridynoline (Dpd) and calcium/creatinin ratio (CalCrea) in systemic lupus erythematosus (SLE) patients and in the control group, (all values are mean ± SD). 
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DISCUSSION
The bone loss may occur in about 25 to 30 percent of SLE patients [10] . Gcs treatment is thought to be the main cause of bone loss in SLE and its effect is dose dependent [11] [12] [13] . Moreover, the degree of bone loss is also connected with the course of SLE as a consequence of the activity of the inflammatory process. The changes are found especially in trabecular bone and to lesser degree in cortical bone [14] . The most important and the most serious results of osteoporosis are fractures. The risk of fractures is determined by peak bone mass, which people reach in their twenties [15] and which is influenced by hormonal function, diet, and some environmental factors [16, 17] . In SLE, fractures are observed less frequently than in some other rheumatic conditions, e.g., rheumatoid arthritis
Glucocorticoids inhibit bone formation by blocking proliferation of osteoblasts.
